BP-897

BP-897

Clinical data
ATC code	none
Identifiers
IUPAC name N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide
CAS Number	314776-92-6 Y
PubChem CID	3038495
IUPHAR/BPS	7625
ChemSpider	2302059 N
UNII	20PLE5W821
ChEMBL	ChEMBL25236 N
CompTox Dashboard (EPA)	DTXSID60953482
ECHA InfoCard	100.150.041
Chemical and physical data
Formula	C26H31N3O2
Molar mass	417.553 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1ccccc1N3CCN(CC3)CCCCNC(=O)c4ccc2ccccc2c4
InChI InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30) N Key:MNHDKMDLOJSCGN-UHFFFAOYSA-N N
NY (what is this?)  (verify)

BP-897 is a drug used in scientific research which acts as a potent selective dopamine D₃ receptor partial agonist with an in vitro intrinsic activity of ~0.6 and ~70x greater affinity for D₃ over D₂ receptors and is suspected to have partial agonist or antagonist activity in vivo. It has mainly been used in the study of treatments for cocaine addiction. A study comparing BP-897 with the potent, antagonistic, and highly D₃ selective SB-277,011-A found, "SB 277011-A (1–10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."